4. Late Stage Oncology Pipeline ~ $500 M Pexiganan ~ $350 M FDA Approved MuGard ™ Non-core Dermatology Assets Being Partnered/Sold >$600 M Thiarabine >$100 M EcoNail Product Oncology Pipeline Pre-clinical IND Phase 1 Phase 2 Phase 3 Potential ProLindac™ ~ $3 B Angiolix mAb >$1 B Other preclinical Includes Prodrax and phenylbutyrate > $500 M VB-12 Oral Delivery Developing under partnership arrangements (insulin, HGH)
5.
6.
7. ProLindac ™ - More Platinum, More Safely Unique design enables more platinum delivery, with fewer side effects Represents “equi-toxic” doses of ProLindac and Eloxatin DACH Platinum (same active in Eloxatin) is inactive while attached to polymer background Chelator releases platinum compound in low pH environment; e.g. tumor
8.
9.
10.
11.
12. Cobalamin-coated Nanopolymer Platform The nanoparticle coated with Cobalamin (red) binds to intrinsic factor (1), which in turn binds to its cell surface receptor (2). The nanoparticle is transported across the cell (3), crosses the gut wall and enters the bloodstream (4). Using The Body’s Own Vitamin Absorption System To Enable and Enhance Delivery of Drugs Through Gut Wall The “Trojan Horse” Delivery Vehicle Nanopolymer “payload” can be Insulin, growth hormone, EPO, etc. 1 2 3 4